B-333 Squamous Cell Carcinoma Antigen Immunoassay Comparability Between Two Commercially Available Analytical Platforms: Abbott Laboratories vs Roche Diagnostics

免疫分析 医学 罗氏诊断公司 可比性 基底细胞 头颈部鳞状细胞癌 肿瘤科 内科学 恶性肿瘤 病理 癌 肿瘤标志物 妇科 头颈部
作者
Nicholas Chin,April Toh,Brenda Quek,SiYu Tan,Chin Pin Yeo
出处
期刊:Clinical Chemistry [American Association for Clinical Chemistry]
卷期号:71 (Supplement_1)
标识
DOI:10.1093/clinchem/hvaf086.720
摘要

Abstract Background Squamous cell carcinoma (SCC) is an epithelial malignancy most commonly found in the lungs, cervix, head and neck due to the widespread location of epithelial lining in these tissues. Squamous Cell Carcinoma Antigen (SCC-Ag) is used as a marker for prognosis and monitoring of recurrence of squamous cell carcinoma. Our laboratory currently measures SCC-Ag on the Abbott Architect I1000SR system. This study aims to evaluate the analytical performance of the Roche Elecsys SCC-Ag immunoassay and its comparability to the current Abbott Architect SCC-Ag immunoassay, with the final goal of consolidating tumor markers testing onto one single analytical platform. Methods Analytical performance of Roche Elecsys SCC assays was assessed using our laboratory-established technical performance evaluation protocol, which is referenced to CLSI Guidelines. This includes 1) assay imprecision, 2) linearity assessment of analytical measurement range, 3) analytical sensitivity and 4) carry-over study. Method comparison was performed by analysing anonymised patient samples (n=79) on both current Abbott Architect SCC-Ag immunoassay (current) and new Roche Elecsys SCC-Ag immunoassay (new). Statistical analysis was performed using Analyze-It v6.15 software. Results Study results demonstrated that imprecision, linearity, analytical sensitivity and carryover for Roche Elecsys SCC assays are within specifications (within-run and total CVs are <5%, linearity study recoveries of ± 10 %, LOD of 0.20 ng/mL and carryover of <1SD differences, respectively). Method comparison showed a good correlation between Roche Elecsys SCC assay and Abbott Architect SCC assay (Altman-Bland percent difference of +4.85% (95%CI of 3.032-6.668%), Passing Bablok regression equation of [Elecys SCC] = 0.9971 [Architect SCC] + 0.2953, Spearman correlation coefficient, R2 = 0.997). Conclusion The Roche Elecsys SCC assay demonstrated good assay performance specifications and acceptable comparison with the current Abbott Architect SCC assay. This study supports the laboratory’s plan to transit SCC-Ag assay from the Abbott platform to Roche platform, consolidating all tumour markers onto a single platform and more streamlined laboratory work processes.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
动听翠萱完成签到,获得积分10
刚刚
04d的应助被正直的黑猫采纳,获得10
刚刚
如意元霜发布了新的文献求助10
1秒前
1秒前
QQ发布了新的文献求助10
1秒前
weddcf发布了新的文献求助10
2秒前
2秒前
cb666发布了新的文献求助10
2秒前
重要无招完成签到,获得积分10
2秒前
2秒前
lulufighting完成签到,获得积分10
3秒前
1820发布了新的文献求助10
3秒前
FF完成签到 ,获得积分10
3秒前
3秒前
lya完成签到,获得积分10
3秒前
yhy完成签到,获得积分10
3秒前
七听的应助被六六采纳,获得30
4秒前
4秒前
英姑的应助被梦在彼岸采纳,获得10
4秒前
5秒前
5秒前
Maestro_S的应助被远方采纳,获得10
5秒前
5秒前
田様的应助被qq1640564935采纳,获得10
5秒前
slowstar完成签到,获得积分10
5秒前
lucia完成签到,获得积分10
6秒前
花城完成签到 ,获得积分10
6秒前
6秒前
月羽完成签到,获得积分10
7秒前
传奇3的应助被材料牛马采纳,获得10
7秒前
7秒前
weddcf完成签到,获得积分10
7秒前
谦让的乐枫完成签到,获得积分10
8秒前
xdlongchem发布了新的文献求助10
8秒前
苒苒完成签到,获得积分10
8秒前
共享精神的应助被yangyanan采纳,获得10
8秒前
ying完成签到,获得积分10
8秒前
LOTUS完成签到,获得积分10
8秒前
Ava的应助被张思佳采纳,获得10
8秒前
Rolly发布了新的文献求助10
8秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
Social Psychology in the Real World 600
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8180617
求助须知:如何正确求助?哪些是违规求助? 9570702
关于积分的说明 21813868
捐赠科研通 7776860
什么是DOI,文献DOI怎么找? 3433294
关于科研通互助平台的介绍 2557571
邀请新用户注册赠送积分活动 2479253